• Welcome, Guest. Please login or register.
    August 26, 2019, 06:10:12 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andy@thalpal.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2019





55097 Posts in 5864 Topics by 6146 Members
Latest Member: cdarr

This is Thalassemia Patients and Friends,
dedicated to its founder,
Lisa Cammilleri.
(1970-2004)
« previous next »
Pages: 1 Go Down Print
Author Topic: PTG 300 Drug  (Read 373 times)
tahirkhan
New Member
*
Offline Offline

Posts: 5


« on: January 15, 2019, 09:46:01 AM »

United States based Protagonist Therapeutics has dosed the first patient in a Phase II trial of PTG-300 for the treatment of #patients with beta #thalassemia.

The PTG-300 drug is actually an injectable hepcidin mimetic in clinical development, which has delivered encouraging results in the treatment of the disease.

Hepcidin is a natural peptide, in other words a critical regulatory hormone governing iron absorption, recycling and utilization by the body.

PTG-300 has been granted Orphan Drug designation in the U.S. and EU and has received Fast Track designation by the FDA for development in the treatment of beta thalassemia.

Initial results are expected to be reported by the company in the second half of 2019.

https://www.prnewswire.com/news-releases/protagonist-therapeutics-initiates-phase-2-trial-of-novel-hepcidin-mimetic-ptg-300-for-the-treatment-of-patients-with-beta-thalassemia-300775348.html
Logged
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!